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Potential control of antipsychotic-induced hyperprolactinemia and obesity in 
children and adolescents by aripiprazole 
Abstract 
The paper published in your journal by Migiliardi et al. (2009) reported that increased hyperprolactinemia 
is a major side-effect of risperidone and olanzapine treatment in children and adolescents. They showed 
that risperidone could cause 10 times higher prolactin levels than olanzapine treatment in children and 
adolescents. This was a well-designed study that controlled for dose, gender, and individual differences, 
as well as response differences to treatment duration (Migliardi et al. 2009). However, another important 
issue that should be considered, but was not reported in this study, is antipsychotic-induced weight gain/
obesity. Clinical data have demonstrated that weight gain is a major side-effect induced by atypical 
antipsychotics, which may lead to medical and social consequences, such as type II diabetes, 
cardiovascular disease. It is particularly important that children and adolescents are more sensitive than 
adults to atypical antipsychotic-induced weight gain/obesity, and other metabolic side-effects (Correll 
2008). Clinical studies have shown that olanzapine treatment can cause far greater weight gain than 
risperidone in both adult and child/adolescent patients (Correll 2008). Therefore, it would be of great 
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Sir, 
The paper published in your journal by Migiliardi et al. (2009) reported that increased 
hyperprolactinemia is a major side-effect of risperidone and olanzapine treatment in children 
and adolescents. They showed that risperidone could cause 10 times higher prolactin levels 
than olanzapine treatment in children and adolescents. This was a well-designed study that 
controlled for dose, gender, and individual differences, as well as response differences to 
treatment duration (Migliardi et al. 2009). However, another important issue that should be 
considered, but was not reported in this study, is antipsychotic-induced weight gain/obesity. 
Clinical data have demonstrated that weight gain is a major side-effect induced by atypical 
antipsychotics, which may lead to medical and social consequences, such as type II diabetes, 
cardiovascular disease. It is particularly important that children and adolescents are more 
sensitive than adults to atypical antipsychotic-induced weight gain/obesity, and other 
metabolic side-effects (Correll 2008). Clinical studies have shown that olanzapine treatment 
can cause far greater weight gain than risperidone in both adult and child/adolescent patients 
(Correll 2008). Therefore, it would be of great value to present body weight data along with 
prolactin data in Migliardi et al.’s study.  
 
One key issue is how to control antipsychotic-induced hyperprolactinemia and weight gain at 
the same time. Prolactin is secreted from pituitary lactotroph cells and primarily inhibited by 
dopamine D2 receptors. As D2 receptor antagonists, blockage of D2 receptors in the 
dopaminergic tubero-infundibular pathway has been suggested as a major mechanism for 
antipsychotic-induced hyperprolactinemia (Correll 2008). In fact, the relative incidence of 
hyperprolactinemia (roughly Risperidone > Haloperidol > Olanzapine > Ziprasidone > 
Quetiapine > Clozapine > Aripiprazole) could be predicted by their potency as D2 antagonists 
(Correll and Carlson 2006). Aripiprazole has even been reported to decrease prolactin 
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secretion in adults (Hoffer et al. 2009). On the other hand, H1 receptor antagonist properties 
are the main predictor for the development of antipsychotic-induced weight gain 
(approximately Clozapine > Olanzapine > Risperidone > Haloperidol > Ziprasidone > 
Aripiprazole   (Correll 2008). Consistent with these findings, olanzapine significantly reduced 
H1 receptor mRNA expression in the hypothalamic arcuate nucleus (Arc) and ventromedial 
hypothalamic nucleus, and H1 receptor mRNA expression in the Arc was negatively 
correlated with food intake and fat mass (Han et al. 2008). It is very interesting that 
olanzapine- and clozapine-induced weight gain/obesity can be successfully controlled by co-
administration with aripiprazole in adult schizophrenia patients, without reducing the original 
olanzapine and clozapine doses (Henderson et al. 2009). Aripiprazole was developed as a 
potent D2 partial-agonist, 5-HT1A partial-agonist, and also 5-HT2A antagonist (DeLeon et al. 
2004). However, aripiprazole has a low histaminergic antagonism and does not affect H1 
receptor expression (DeLeon et al. 2004; Han et al. 2008). Instead, aripiprazole is not a simple 
partial-agonist, but a functionally selective drug that can act as a D2 agonist or D2 antagonist 
depending on different brain regions (Han et al. 2009). Based on these findings, we recently 
suggested that aripiprazole’s D2 agonistic property may account for the effect of aripiprazole 
in reducing olanzapine-induced obesity (Deng et al. 2010). It is possible that a co-
administration of aripiprazole could be used to control risperidone-induced 
hyperprolactinaemia through its D2 agonistic effect. In fact, a recent study has found that 
risperidone treatment adjunctive with aripiprazole significantly decreased ~10 times prolactin 
levels compared to adjunctive placebo in adults (Kane et al. 2009). It is very important that 
aripiprazole has been approved by the FDA to be used in youths (aged 13 years and older) for 
schizophrenia and bipolar disorder, as well as for autism spectrum disorder in children aged 6 
to 17 years in 2009. Therefore, it is possible to use aripiprazole in children or adolescents to 
reduce both olanzapine-induced weight gain and risperidone-induced hyperprolactinemia. 
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However, further animal studies and clinical trials are necessary before any extended practices 
are adopted in the paediatric clinics. 
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